What causes giant cell arteritis

Overview

Giant Cell Arteritis (GCA), often referred to as temporal arteritis, is a chronic inflammatory disorder that primarily affects the large and medium-sized arteries of the body. It is a type of vasculitis, which means it involves inflammation of the blood vessel walls. This inflammation can cause the arteries to swell, narrow, or become scarred, potentially leading to a reduction in blood flow to vital organs and tissues. GCA is most common in individuals over the age of 50, with the incidence increasing with age. It disproportionately affects women and individuals of Northern European descent. The condition is considered an autoimmune disease, meaning the body's immune system, which normally protects against foreign invaders like bacteria and viruses, mistakenly attacks its own healthy tissues.

What is Giant Cell Arteritis?

Giant Cell Arteritis is a systemic inflammatory condition that primarily targets arteries. The hallmark of GCA is the presence of 'giant cells' (multinucleated cells) and inflammation within the walls of affected arteries, particularly the cranial arteries, such as the temporal arteries that run along the sides of the head. However, it can also affect other arteries, including the aorta and its branches, as well as arteries in the eyes, brain, spinal cord, and limbs. The inflammation causes the inner lining of the arteries to thicken, which can lead to narrowing (stenosis) or even complete blockage (occlusion) of the blood vessel. This reduced blood flow can deprive tissues and organs of oxygen and nutrients, leading to a variety of symptoms and potential complications.

What Causes Giant Cell Arteritis?

The precise cause of Giant Cell Arteritis is not fully understood, but it is generally believed to be an autoimmune disorder. In autoimmune diseases, the immune system malfunctions and begins to attack the body's own cells and tissues. In the case of GCA, the immune system targets the arteries, leading to inflammation. Several factors are thought to contribute to the development of GCA:

1. Autoimmune Response:

The prevailing theory is that an abnormal immune response is central to GCA. Certain immune cells and inflammatory mediators are activated, leading to the characteristic inflammation in the arterial walls. This inflammation involves various types of white blood cells, including lymphocytes and macrophages, which can aggregate and form the characteristic 'giant cells' observed under a microscope in a biopsy sample. These cells, along with other inflammatory infiltrates, damage the arterial wall structure.

2. Genetic Predisposition:

Research suggests that certain genetic factors may increase an individual's susceptibility to developing GCA. Specific human leukocyte antigen (HLA) genes, which play a role in the immune system's ability to distinguish self from non-self, have been associated with an increased risk of GCA. While having these genes doesn't guarantee the development of the disease, it may make individuals more vulnerable when exposed to certain triggers.

3. Environmental Triggers:

It is hypothesized that an environmental factor, such as an infection (viral or bacterial), may trigger the autoimmune response in genetically susceptible individuals. However, no specific infectious agent has been definitively identified as the cause of GCA. The theory is that an infection might mimic certain proteins found in the arterial walls, leading the immune system to mistakenly attack these vessels as if they were foreign invaders. This could initiate or perpetuate the chronic inflammation seen in GCA.

4. Age:

GCA is overwhelmingly a disease of older adults. It is rarely diagnosed in individuals under the age of 50, and the incidence rises significantly after this age. The aging immune system may undergo changes that make it more prone to developing autoimmune conditions like GCA.

5. Sex and Ethnicity:

GCA is more common in women than in men, with a ratio of approximately 2:1 or 3:1. It is also more prevalent in people of Northern European descent. These demographic patterns suggest that hormonal factors and specific genetic backgrounds may play a role in disease development.

Risk Factors and Associations

While the exact cause is unknown, several factors are associated with an increased risk of developing GCA:

• Age: Being over 50 years old is the most significant risk factor.
• Sex: Women are more likely to develop GCA than men.
• Ethnicity: Individuals of Northern European descent have a higher incidence.
• Geographic Location: GCA is more common in Scandinavian countries and areas with a high proportion of people of Northern European ancestry.
• Polymyalgia Rheumatica (PMR): GCA frequently co-occurs with polymyalgia rheumatica, another inflammatory condition that causes muscle pain and stiffness, particularly in the shoulders and hips. Up to 50% of people with PMR may develop GCA, and conversely, about 15-20% of people with GCA may have symptoms of PMR.

It is important to note that GCA is not caused by lifestyle factors such as diet or stress, although these can influence overall health and the management of chronic conditions. The development of GCA is primarily driven by the complex interplay of the immune system, genetics, and potentially environmental exposures.

Symptoms and Diagnosis

Symptoms of GCA can be varied and often develop gradually. Common symptoms include new-onset headache (often localized to the temples), scalp tenderness, jaw claudication (pain in the jaw muscles when chewing), visual disturbances (such as blurred vision, double vision, or temporary or permanent vision loss), fever, fatigue, weight loss, and stiffness in the shoulders and hips (polymyalgia rheumatica symptoms). Due to the potential for rapid vision loss, prompt diagnosis is critical. Diagnosis typically involves a combination of clinical symptoms, blood tests (measuring inflammatory markers like ESR and CRP), and often a temporal artery biopsy to confirm the presence of inflammation and giant cells. Imaging techniques like ultrasound or MRI may also be used.

Treatment and Management

The primary treatment for GCA is high-dose corticosteroid medication, such as prednisone. These medications are very effective at reducing inflammation and relieving symptoms, and they are crucial for preventing vision loss and other serious complications. Treatment usually needs to continue for an extended period, often 1-2 years or longer, with the dose gradually tapered down. Other immunosuppressive medications may be used in conjunction with or as an alternative to corticosteroids for patients who do not respond well to steroids or who experience significant side effects. Regular monitoring by a rheumatologist is essential to manage the condition effectively and adjust treatment as needed.